Pre-PD

REM Sleep Behavior Disorder as a Pathway to Dementia: If, When, How, What, and Why Should Physicians Disclose the Diagnosis and Risk for Dementia

We provide an approach to risk disclosure for patients with iRBD. Patients should be asked if they want to know about future risks. If so, disclosure should be patient centered, focusing on what might happen. Discussion should occur early to give patients time to prepare for the future and consider participating in research. CLICK TO […]

REM Sleep Behavior Disorder as a Pathway to Dementia: If, When, How, What, and Why Should Physicians Disclose the Diagnosis and Risk for Dementia Read More »

Temporal trajectory of biofluid markers in Parkinson’s disease

At baseline, PD patients showed lower CSF α-syn, Aβ, t-tau and p-tau levels than those of the controls. In all PD patients, CSF α-syn and Aβ decreased in a negative exponential pattern before the onset of motor symptoms, whereas CSF t-tau and p-tau, and serum NfL increased. Patients with cognitive impairment exhibited faster decline of

Temporal trajectory of biofluid markers in Parkinson’s disease Read More »

Neuroprotective effect of Lactobacillus plantarum DP189 on MPTP-induced Parkinson’s disease model mice

The results indicated that L. plantarum DP189 improved behavioral ability and increased the levels of 5-hydroxytryptamine and dopamine of PD mice. L. plantarum DP189 significantly increased the positive rate of tyrosine hydroxylase cells. L. plantarum DP189 activated the ERK2 and AKT/mTOR pathways, promoted the expression of Bcl-2, and inhibited the activities of Bax and Caspase 3. The results indicated that L. plantarum DP189

Neuroprotective effect of Lactobacillus plantarum DP189 on MPTP-induced Parkinson’s disease model mice Read More »

IMPACT OF THE SHORT – CHAIN FATTY ACIDS ON THE MICROBIOTA – GUT – BRAIN AXIS

Studies show that short – chain fatty acids have differenteffects by increasing or decreasing the quantity of certain molecules such as GLP-1,peptide YY, insulin, glucagon, ghrelin, leptin and serotonin while they also have animpact on the nervous system. Also is needed to emphasize its role in certainneurological diseases such as Parkinson, autism spectrum disorder and

IMPACT OF THE SHORT – CHAIN FATTY ACIDS ON THE MICROBIOTA – GUT – BRAIN AXIS Read More »

Probiotics and the Treatment of Parkinson’s Disease: An Update

Probiotic supplementation mediates these pharmacological effects by targeting a variety of cellular and molecular processes, i.e., oxidative stress, inflammatory and anti-inflammatory pathways, as well as apoptosis. Herein, we summarize the effects of probiotics on motor and non-motor symptoms as well as various cellular and molecular pathways in PD. CLICK TO REVIEW

Probiotics and the Treatment of Parkinson’s Disease: An Update Read More »

Association of Gut Microbiome Dysbiosis with Neurodegeneration: Can Gut Microbe-Modifying Diet Prevent or Alleviate the Symptoms of Neurodegenerative Diseases?

However, there is limited success in restoring healthy microbial biodiversity in AD and PD patients with general probiotics interventions and fecal microbial therapies. Fortunately, the gut microflora is susceptible to long-term extrinsic influences such as lifestyle and dietary choices, providing opportunities for treatment through comparatively individual-specific control of human behavior. In this review, weexamine the

Association of Gut Microbiome Dysbiosis with Neurodegeneration: Can Gut Microbe-Modifying Diet Prevent or Alleviate the Symptoms of Neurodegenerative Diseases? Read More »

Modulation of Neuroinflammation by the Gut Microbiota in Prion and Prion-Like Diseases

One fundamental component of systemic homeostasis is the gut microbiota, which communicates withthe CNS via microbial metabolite production, the peripheral nervous system, and regulation oftryptophan metabolism. Over the past 10–15 years, research focused on the microbiota–gut–brainaxis has culminated in the discovery that dysbiosis, or an imbalance between commensal andpathogenic gut bacteria, can promote CNS pathologies.

Modulation of Neuroinflammation by the Gut Microbiota in Prion and Prion-Like Diseases Read More »

Cutaneous Alpha-Synuclein is Correlated with Autonomic Impairment in Isolated REM Sleep Behavior Disorder

The presence of p-syn at any biopsy site was correlated with both sympathetic (CASS adrenergic r = 0.6, p < 0.05) and total autonomic impairment (CASS total r = 0.6, p < 0.05) on autonomic reflex testing in iRBD patients. These results were independent of the density of p-syn at each site. There was no

Cutaneous Alpha-Synuclein is Correlated with Autonomic Impairment in Isolated REM Sleep Behavior Disorder Read More »

Influence of probiotic bacteria on gut microbiota composition and gut wall function in an in-vitro model in patients with Parkinson’s disease

In general, the relative proportions of the main bacterial phyla in the microbiotas of PD patients differed from those of healthy subjects, with levels of Firmicutes raised and levels of Bacteroidetes reduced. Dosing with probiotic resulted in a change in bacterial composition in the microbiotas over a 48 h period. Several other indicators of gut health changed upon dosing with

Influence of probiotic bacteria on gut microbiota composition and gut wall function in an in-vitro model in patients with Parkinson’s disease Read More »

Non-motor symptoms and their use as markers for prodromal and early Parkinson’s Disease

Parkinson’s Disease (PD) is the second most common neurodegenerative disorder. It is a disease with a broad spectrum of symptoms, both motor and non-motor, but is often only diagnosed when the motor symptoms begin to appear. By this time however, a large amount of the dopaminergic neurons of the substantia nigra pars compacta have already

Non-motor symptoms and their use as markers for prodromal and early Parkinson’s Disease Read More »